Bitcoin investment company Parataxis Holdings LLC announced that it has reached a final investment agreement worth 25 billion won with Bridge Biotherapeutics, Inc. This deal gives it control over the latter, and after the transaction is completed, Bridge Biotherapeutics will be renamed Parataxis Korea and will continue to be listed on the KOSDAQ market in South Korea. The company is expected to provide more details about this transaction after holding a shareholders' meeting in August.
According to previous reports, Parataxis Holdings LLC plans to go public through a merger with special purpose acquisition company SilverBox Corp IV, with both parties having signed a non-binding letter of intent.